iBloC: a ground-breaking translational bladder cancer-on-chip model to empower development of novel immuno-oncology drugs

• Unité de recherche: INNOSUISSE
• Numéro de projet: 104.320 IP-LS
• Titre du projet anglais: iBloC: a ground-breaking translational bladder cancer-on-chip model to empower development of novel immuno-oncology drugs

Mots-clé (Anglais)

Life sciences, Biotechnology and processing

Résumé des résultats (Abstract) (Anglais)

The consortium will develop iBloC ? a novel drug screening platform that will accelerate and improve drug development for bladder cancer therapies. Here, we will deliver the first iBloC kit tailored to bladder cancer research, which will be ready to enter the market in Q1 2025.